Evidence map›Paper›PMID 37111714›Full record

ArticlePharmaceutics2023

Injectable In-Situ Forming Depot Based on PLGA and PLGA-PEG-PLGA for Sustained-Release of Risperidone: In Vitro Evaluation and Pharmacokinetics in Rabbits.

Seyedeh Nesa Rezaeian Shiadeh, Farzin Hadizadeh, Elham Khodaverdi, Mahmoud Gorji Valokola, Saleh Rakhshani, Hossein Kamali, Ali Nokhodchi

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Journal of the American Chemical Society · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Seyedeh Nesa Rezaeian ShiadehDepartment of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad 9177948974, Iran.
Farzin HadizadehBiotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad 9177948974, Iran.ORCID 0000-0002-7680-8191
Elham KhodaverdiTargeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad 9177948974, Iran.ORCID 0000-0002-1084-6603
Mahmoud Gorji ValokolaDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad 9177948974, Iran.
Saleh RakhshaniDepartment of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad 9177948974, Iran.
Hossein KamaliTargeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad 9177948974, Iran.
Ali NokhodchiLupin Pharmaceutical Research Center, 4006 NW 124th Ave., Coral Springs, Florida, FL 33065, USA.ORCID 0000-0002-3244-2482
Mashhad University of Medical Sciences · IRUniversity of Sussex · GB

Funding

Mashhad University of Medical Sciences 1396.212
6 · The paper itself

Abstract

In the current research, novel drug delivery systems based on in situ forming gel (ISFG) (PLGA-PEG-PLGA) and in situ forming implant (ISFI) (PLGA) were developed for one-month risperidone delivery. In vitro release evaluation, pharmacokinetics, and histopathology studies of ISFI, ISFG, and Risperdal CONSTA

Indexed as

ISFGISFIPLGAPLGA-PEG-PLGARisperdal CONSTA®risperidone

Identifiers

PMID37111714
PMCPMC10143068
OpenAlexW4365453808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.